secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2026-10-09T12:15:15+00:00
Accession:  0001193125-26-418560
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 3.03, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Atossa declares stapled CVRs giving holders 25% of first PRV proceeds, $50M cap; record date Oct 19, 2026
--------------------------------------------------------------------------------

- Board declared one stapled CVR per ATOS share outstanding at the Oct 19, 2026 record date; shares issued after that also carry one CVR until detachment or expiry.
- CVR holders get 25% of net proceeds from sale or deemed monetization of Atossa's first qualifying FDA priority review voucher, capped at $50M aggregate.
- CVRs apply to a first qualifying PRV awarded on or before Dec 31, 2036 (Board may extend); no PRV has been awarded and (Z)-endoxifen is not approved for any indication.
- (Z)-endoxifen holds FDA Rare Pediatric Disease Designation for Duchenne muscular dystrophy and McCune-Albright syndrome; VStock Transfer, LLC is rights agent.
- CVRs stay stapled to shares with no separate CUSIP or trading; using the voucher or a change of control while unsold is a deemed monetization valued by an independent advisor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526418560/0001193125-26-418560-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526418560/atos-20261008.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-418560

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer